How many insider trades does FilingIQ track for TBPH?

FilingIQ tracks 602 Form 4 insider transactions for TBPH (Theravance Biopharma, Inc.), covering filings from Feb 20, 2015 onwards. 12 of those were filed in the last 90 days.

Are TBPH insiders net buyers or net sellers?

Across the full Form 4 history for TBPH, 17 transactions (3%) were open-market purchases and 71 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does TBPH insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is TBPH in?

Theravance Biopharma, Inc. (TBPH) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $978.01M.

TBPH insider trading

NasdaqGM Healthcare

Theravance Biopharma, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

602

Last 90 days

Buys / sells

3% / 12%

Market cap

$978.01M

About Theravance Biopharma, Inc.

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Company website: www.theravance.com

TBPH insider activity at a glance

FilingIQ has scored 602 insider transactions for TBPH since Feb 20, 2015. The most recent filing in our index is dated Apr 1, 2026.

Across the full history, 17 open-market purchases and 71 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on TBPH insider trades is 55.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live TBPH trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for TBPH?: FilingIQ tracks 602 Form 4 insider transactions for TBPH (Theravance Biopharma, Inc.), covering filings from Feb 20, 2015 onwards. 12 of those were filed in the last 90 days.
Are TBPH insiders net buyers or net sellers?: Across the full Form 4 history for TBPH, 17 transactions (3%) were open-market purchases and 71 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does TBPH insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is TBPH in?: Theravance Biopharma, Inc. (TBPH) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $978.01M.

Methodology & sources

Every TBPH insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.